Stock Financial Ratios, Dividends, Split History

VIRT / Virtu Financial, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)2,361.02
Enterprise Value ($M)3,303.71
Book Value ($M)999.95
Book Value / Share10.93
Price / Book2.36
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 62,579,147
Common Shares Outstanding3 79,610,490
Weighted Average Number Of Shares Outstanding Basic 62,579,147
Common Shares Outstanding2 17,066,564
Common Shares Outstanding 91,512,582
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.01
Return on Assets (ROA)0.01
Return on Equity (ROE)0.13
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Technology Services Revenue116,503,000.00
Other Sales Revenue Net95,045,000.00
Financial Services Revenue0.00
Net Income18.90
Earnings Per Share Diluted0.03
Earnings Per Share Basic0.03
Cash Flow Statement (mra) ($M)
Cash From Operations290.57
Cash from Investing-838.02
Cash from Financing-838.02
Identifiers and Descriptors
Central Index Key (CIK)1592386
Related CUSIPS
928254901 928254951

Split History

Stock splits are used by Virtu Financial, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

23m - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

1h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

22h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

10 A-Rated Financial Stocks to Consider | InvestorPlace

2018-07-13 investorplace
JPMorgan Chase & Co (NYSE: JPM) came in with some bullish numbers this morning, with revenue up 18% for the most recent quarter. Not all the big banks were as bullish, but it does show that the financial sector is finally finding a way to make money more consistently without relying on the risky derivatives market. (21-0)

Morgan Stanley Hires Electronic Trading Vet for Bond Effort - Bloomberg

2018-06-26 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (24-2)

Top Analyst Upgrades and Downgrades: Celgene, Cypress Semi, Intuit, KemPharm, Oasis Petroleum, Rio Tinto, Shake Shack and More

2018-05-23 247wallst
Stocks were up earlier this week, but fresh warnings that a North Korea summit might not actually happen in June weighed on the indexes on Wednesday. The trend of buying the dips has not worked as well as it has in prior years, and many investors have been considering how they want their investments positioned for the longer term. (164-5)

Why Virtu Financial (VIRT) Might Be a Diamond in the Rough

2018-05-22 zacks
It can be very difficult to find companies that are both flying under the radar, and still might have potential for gains. Many times, stocks are off investors’ radar screens for a reason, though there are some hidden gems that could be worth uncovering by those with a high risk tolerance. (36-2)

Synchrony Financial Plans to Enhance Shareholders' Value

2018-05-21 zacks
In its concerted efforts to increase shareholder value, the board of directors of Synchrony Financial (SYF - Free Report) has announced a plan to hike the quarterly dividend by 94%, effective third-quarter 2018. The company would pay a dividend of 21 cents per share to shareholders of record as of Mar 31, 2018. (9-1)

CUSIP: 928254101